The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cells

Leukemia and Lymphoma

Volumn 49, Issue 8, 2008, Pages 1567-1577

  Ozer, Ozden ^a   Zhao, Yi D ^a   Ostler, Kelly R ^a   Akin, Cem ^b   Anastasi, John ^a   Vardiman, James W ^a   Godley, Lucy A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Alternative splicing; KIT; Mast cell leukemia; Systemic mastocytosis

Indexed keywords

ADENOSINE TRIPHOSPHATE; CD34 ANTIGEN; COMPLEMENTARY DNA; ISOPROTEIN; PROTEIN KIT; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOPHOSPHORYLATION; BINDING SITE; BLAST CELL; BONE MARROW; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MAST CELL LEUKEMIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; SYSTEMIC MASTOCYTOSIS; UMBILICAL CORD BLOOD; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; ALTERNATIVE SPLICING; ANTIGENS, CD34; BINDING SITES; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MAST-CELL; MASTOCYTOSIS; MASTOCYTOSIS, SYSTEMIC; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-KIT; RNA, MESSENGER; RNA, NEOPLASM; SEQUENCE DELETION;

EID: 51349107061     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802140865     Document Type: Article

References (69)

1. Yarden, Y., Kuang, W. J., Yang-Feng, T., Coussens, L., Munemitsu, S. Dull, T. J. et al. (1987) Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand. Embo J, 6, pp. 3341-3351.
2. Qiu, F. H., Ray, P., Brown, K., Barker, P. E., Jhanwar, S. Ruddle, F. H. et al. (1988) Primary structure of c-kit: Relationship with the CSF-1/ PDGF receptor kinase family-oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. Embo J, 7, pp. 1003-1011.
3. Zsebo, K. M., Williams, D. A., Geissler, E. N., Broudy, V. C., Martin, F. H. Atkins, H. L. et al. (1990) Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell, 63, pp. 213-224.
4. Zhang, Z., Zhang, R., Joachimiak, A., Schlessinger, J. and Kong, X. P. (2000) Crystal structure of human stem cell factor: Implication for stem cell factor receptor dimerization and activation. Proc Natl Acad Sci USA, 97, pp. 7732-7737.
5. Hubbard, S. R. (2004) Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat Rev Mol Cell Biol, 5, pp. 464-471.
6. Mol, C. D., Dougan, D. R., Schneider, T. R., Skene, R. J., Kraus, M. L. Scheibe, D. N. et al. (2004) Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem, 279, pp. 31655-31663.
7. Orfao, A., Garcia-Montero, A. C., Sanchez, L. and Escribano, L. (2007) Recent advances in the understanding of mastocytosis: The role of KIT mutations. Br J Haematol, 138, pp. 12-30.
8. Simmons, P. J., Aylett, G. W., Niutta, S., To, L. B., Juttner, C. A. and Ashman, L. K. (1994) c-kit is expressed by primitive human hematopoietic cells that give rise to colony-forming cells in stroma-dependent or cytokine-supplemented culture. Exp Hematol, 22, pp. 157-165.
9. Metcalfe, D. D. (2005) Regulation of normal and neoplastic human mast cell development in mastocytosis. Trans Am Clin Climatol Assoc, 116, pp. 185-203.
10. Huizinga, J. D., Thuneberg, L., Kluppel, M., Malysz, J., Mikkelsen, H. B. and Bernstein, A. (1995) W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature, 373, pp. 347-349.
11. Strohmeyer, T., Reese, D., Press, M., Ackermann, R., Hartmann, M. and Slamon, D. (1995) Expression of the c-kit proto-oncogene and its ligand stem cell factor (SCF) in normal and malignant human testicular tissue. J Urol, 153, pp. 511-515.
12. Sekido, Y., Obata, Y., Ueda, R., Hida, T., Suyama, M. Shimokata, K. et al. (1991) Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res, 51, pp. 2416-2419.
13. Bene, M. C., Bernier, M., Casasnovas, R. O., Castoldi, G., Knapp, W. Lanza, F. et al. (1998) The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). Blood, 92, pp. 596-599.
14. Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T. Ishiguro, S. et al. (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 279, pp. 577-580.
15. Andersson, J., Sjogren, H., Meis-Kindblom, J. M., Stenman, G., Aman, P. and Kindblom, L. G. (2002) The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol, 160, pp. 15-22.
16. Emile, J. F., Theou, N., Tabone, S., Cortez, A., Terrier, P. Chaumette, M. T. et al. (2004) Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol, 2, pp. 597-605.
17. Kemmer, K., Corless, C. L., Fletcher, J. A., McGreevey, L., Haley, A. Griffith, D. et al. (2004) KIT mutations are common in testicular seminomas. Am J Pathol, 164, pp. 305-313.
18. Orfao, A., Ortuno, F., de Santiago, M., Lopez, A. and San Miguel, J (2004) Immunophenotyping of acute leukemias and myelodysplastic syndromes. Cytometry A, 58, pp. 62-71.
19. Lorenzo, F., Nishii, K., Monma, F., Kuwagata, S., Usui, E. and Shiku, H. (2006) Mutational analysis of the KIT gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Leuk Res, 30, pp. 1235-1239.
20. Bacher, U., Haferlach, T., Kern, W., Haferlach, C. and Schnittger, S. (2007) A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica, 92, pp. 744-752.
21. Nakata, Y., Kimura, A., Katoh, O., Kawaishi, K., Hyodo, H. Abe, K. et al. (1995) c-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br J Haematol, 91, pp. 661-663.
22. Feger, F., Ribadeau, A Dumas, Leriche, L., Valent, P. and Arock, M. (2002) Kit and c-kit mutations in mastocytosis: A short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol, 127, pp. 110-114.
23. Akin, C. (2005) Clonality and molecular pathogenesis of mastocytosis. Acta Haematol, 114, pp. 61-69.
24. Horny, H. P., Sotlar, K. and Valent, P. (2007) Mastocytosis: State of the art. Pathobiology, 74, pp. 121-132.
25. Frohling, S., Scholl, C., Gilliland, D. G. and Levine, R. L. (2005) Genetics of myeloid malignancies: Pathogenetic and clinical implications. J Clin Oncol, 23, pp. 6285-6295.
26. Furitsu, T., Tsujimura, T., Tono, T., Ikeda, H., Kitayama, H. Koshimizu, U. et al. (1993) Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest, 92, pp. 1736-1744.
27. Kanakura, Y., Furitsu, T., Tsujimura, T., Butterfield, J. H., Ashman, L. K. Ikeda, H. et al. (1994) Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line. Leukemia, 8, pp. S18-S22.
28. Care, R. S., Valk, P. J., Goodeve, A. C., Abu-Duhier, F. M., Geertsma-Kleinekoort, W. M. Wilson, G. A. et al. (2003) Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol, 121, pp. 775-777.
29. Meshinchi, S., Stirewalt, D. L., Alonzo, T. A., Zhang, Q., Sweetser, D. A. Woods, W. G. et al. (2003) Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood, 102, pp. 1474-1479.
30. Beghini, A., Ripamonti, C. B., Cairoli, R., Cazzaniga, G., Colapietro, P. Elice, F. et al. (2004) KIT activating mutations: Incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica, 89, pp. 920-925.
31. Nanri, T., Matsuno, N., Kawakita, T., Suzushima, H., Kawano, F. Mitsuya, H. et al. (2005) Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). Leukemia, 19, pp. 1361-1366.
32. Wang, Y. Y., Zhou, G. B., Yin, T., Chen, B., Shi, J. Y. Liang, W. X. et al. (2005) AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA, 102, pp. 1104-1109.
33. Cairoli, R., Beghini, A., Grillo, G., Nadali, G., Elice, F. Ripamonti, C. B. et al. (2006) Prognostic impact of c-KIT mutations in core binding factor leukemias: An Italian retrospective study. Blood, 107, pp. 3463-3468.
34. Schnittger, S., Kohl, T. M., Haferlach, T., Kern, W., Hiddemann, W. Spiekermann, K. et al. (2006) KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood, 107, pp. 1791-1799.
35. Gari, M., Goodeve, A., Wilson, G., Winship, P., Langabeer, S. Linch, D. et al. (1999) c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol, 105, pp. 894-900.
36. Boissel, N., Leroy, H., Brethon, B., Philippe, N., de Botton, S. Auvrignon, A. et al. (2006) Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia, 20, pp. 965-970.
37. Paschka, P., Marcucci, G., Ruppert, A. S., Mrozek, K., Chen, H. Kittles, R. A. et al. (2006) Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B Study. J Clin Oncol, 24, pp. 3904-3911.
38. Beghini, A., Peterlongo, P., Ripamonti, C. B., Larizza, L., Cairoli, R. Morra, E. et al. (2000) C-kit mutations in core binding factor leukemias. Blood, 95, pp. 726-727.
39. Goemans, B. F., Zwaan, C. M., Miller, M., Zimmermann, M., Harlow, A. Meshinchi, S. et al. (2008) Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia, 22, pp. 303-307.
40. Shih, L. Y., Liang, D. C., Huang, C. F., Chang, Y. T., Lai, C. L. Lin, T. H. et al. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. Leukemia
41. Shimada, A., Taki, T., Tabuchi, K., Tawa, A., Horibe, K. Tsuchida, M. et al. (2006) KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): A study of the Japanese Childhood AML Cooperative Study Group. Blood, 107, pp. 1806-1809.
42. Corbacioglu, S., Kilic, M., Westhoff, M. A., Reinhardt, D., Fulda, S. and Debatin, K. M. (2006) Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood, 108, pp. 3504-3513.
43. Nagata, H., Worobec, A. S., Oh, C. K., Chowdhury, B. A., Tannenbaum, S. Suzuki, Y. et al. (1995) Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA, 92, pp. 10560-10564.
44. Longley, B. J., Tyrrell, L., Lu, S. Z., Ma, Y. S., Langley, K. Ding, T. G. et al. (1996) Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm. Nat Genet, 12, pp. 312-314.
45. Longley, Jr BJ, Metcalfe, D. D., Tharp, M., Wang, X., Tyrrell, L. Lu, S. Z. et al. (1999) Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA, 96, pp. 1609-1614.
46. Garcia-Montero, A. C., Jara-Acevedo, M., Teodosio, C., Sanchez, M. L., Nunez, R. Prados, A. et al. (2006) KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood, 108, pp. 2366-2372.
47. Buttner, C., Henz, B. M., Welker, P., Sepp, N. T. and Grabbe, J. (1998) Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: A possible explanation for divergent clinical behavior. J Invest Dermatol, 111, pp. 1227-1231.
48. Sotlar, K., Escribano, L., Landt, O., Mohrle, S., Herrero, S. Torrelo, A. et al. (2003) One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol, 162, pp. 737-746.
49. Pignon, J. M., Giraudier, S., Duquesnoy, P., Jouault, H., Imbert, M. Vainchenker, W. et al. (1997) A new c-kit mutation in a case of aggressive mast cell disease. Br J Haematol, 96, pp. 374-376.
50. Pullarkat, V. A., Bueso-Ramos, C., Lai, R., Kroft, S., Wilson, C. S. Pullarkat, S. T. et al. (2003) Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: Analysis of clinicopathologic features and activating c-kit mutations. Am J Hematol, 73, pp. 12-17.
51. Horny, H. P., Sotlar, K., Sperr, W. R. and Valent, P. (2004) Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: A histopathological challenge. J Clin Pathol, 57, pp. 604-608.
52. Nagai, S., Ichikawa, M., Takahashi, T., Sato, H., Yokota, H. Oshima, K. et al. (2007) The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia. Exp Hematol, 35, pp. 1747-1752.
53. Pullarkat, V., Bedell, V., Kim, Y., Bhatia, R., Nakamura, R. Forman, S. et al. (2007) Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res, 31, pp. 261-265.
54. Butterfield, J. H., Weiler, D., Dewald, G. and Gleich, G. J. (1988) Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res, 12, pp. 345-355.
55. Akin, C BK, D'Ambrosio, C., Kirshenbaum, A. S., Ma, Y., Longley, B. J. and Metcalfe, D. D. (2003) Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol, 31, pp. 686-692.
56. Noack, F., Sotlar, K., Notter, M., Thiel, E., Valent, P. and Horny, H. P. (2004) Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V. Leuk Lymphoma, 45, pp. 2295-2302.
57. Ma, Y., Cunningham, M. E., Wang, X., Ghosh, I., Regan, L. and Longley, B. J. (1999) Inhibition of spontaneous receptor phosphorylation by residues in a putative alpha-helix in the KIT intracellular juxtamembrane region. J Biol Chem, 274, pp. 13399-13402.
58. Kitamura, Y., Tsujimura, T., Jippo, T., Kasugai, T. and Kanakura, Y. (1995) Regulation of development, survival and neoplastic growth of mast cells through the c-kit receptor. Int Arch Allergy Immunol, 107, pp. 54-56.
59. Blume-Jensen, P. and Hunter, T. (2001) Oncogenic kinase signalling. Nature, 411, pp. 355-365.
60. Mizushima, S. and Nagata, S. (1990) pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res, 18, p. 5322.
61. Blechman, J. M., Lev, S., Barg, J., Eisenstein, M., Vaks, B. Vogel, Z. et al. (1995) The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell, 80, pp. 103-113.
62. Reith, A. D., Ellis, C., Lyman, S. D., Anderson, D. M., Williams, D. E. Bernstein, A. et al. (1991) Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase. Embo J, 10, pp. 2451-2459.
63. Crosier, P. S., Ricciardi, S. T., Hall, L. R., Vitas, M. R., Clark, S. C. and Crosier, K. E. (1993) Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acute myeloid leukemia. Blood, 82, pp. 1151-1158.
64. Hayashi, S., Kunisada, T., Ogawa, M., Yamaguchi, K. and Nishikawa, S. (1991) Exon skipping by mutation of an authentic splice site of c-kit gene in W/W mouse. Nucleic Acids Res, 19, pp. 1267-1271.
65. Molderings, G. J., Kolck, U. W., Scheurlen, C., Bruss, M., Homann, J. and Von, Kugelgen I. (2007) Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder. Scand J Gastroenterol, 42, pp. 1045-1053.
66. Piao, X., Curtis, J. E., Minkin, S., Minden, M. D. and Bernstein, A. (1994) Expression of the Kit and KitA receptor isoforms in human acute myelogenous leukemia. Blood, 83, pp. 476-481.
67. Akin, C., Fumo, G., Yavuz, A. S., Lipsky, P. E., Neckers, L. and Metcalfe, D. D. (2004) A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood, 103, pp. 3222-3225.
68. Lasota, J., Kopczynski, J., Majidi, M., Miettinen, M. and Sarlomo-Rikala, M. (2002) Apparent KIT Ser(715) deletion in GIST mRNA is not detectable in genomic DNA and represents a previously known splice variant of KIT transcript. Am J Pathol, 161, pp. 739-741.
69. Escribano, L., Garca-Montero, A., Nunez-Lopez, R., Lopez-Jimenez, J., Almeida, J. Prados, A. et al. (2004) Systemic mastocytosis associated with acute myeloid leukemia: Case report and implications for disease pathogenesis. J Allergy Clin Immunol, 114, pp. 28-33.